|
gptkbp:instanceOf
|
gptkb:drug
gptkb:peripherally_acting_μ-opioid_receptor_antagonist
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:ATCCode
|
A06AH03
|
|
gptkbp:blackBoxWarning
|
true
|
|
gptkbp:brand
|
Entereg
|
|
gptkbp:CASNumber
|
170098-28-9
|
|
gptkbp:contraindication
|
patients who have taken therapeutic doses of opioids for more than 7 consecutive days prior to use
|
|
gptkbp:developer
|
Adolor Corporation
|
|
gptkbp:eliminationHalfLife
|
10-17 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C25H32N2O4
|
|
gptkbp:KEGGID
|
D03141
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks peripheral μ-opioid receptors
|
|
gptkbp:metabolism
|
gptkb:gut_flora
|
|
gptkbp:notCrossBloodBrainBarrier
|
true
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:proteinBinding
|
80%
|
|
gptkbp:PubChem_CID
|
CHEMBL1201192
130574
148191
DB06274
|
|
gptkbp:restrictedDistributionProgram
|
Entereg Access Support and Education (E.A.S.E.)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
myocardial infarction risk (long-term use)
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
acceleration of gastrointestinal recovery after bowel resection
postoperative ileus
|
|
gptkbp:bfsParent
|
gptkb:Opioids
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alvimopan
|